Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy; Experimental Imaging Center, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Curr Opin Immunol. 2022 Aug;77:102207. doi: 10.1016/j.coi.2022.102207. Epub 2022 May 16.
Hepatitis B virus (HBV) causes either acute or chronic liver diseases. Chronic hepatitis B (CHB) often progresses to the development of cirrhosis and hepatocellular carcinoma. As HBV is extremely noncytopathic, immunological events play a key role in the infection outcome. Indeed, adaptive immune responses trigger viral clearance during acute infection and viral persistence reflects the failure to generate and maintain such responses. Current therapies for patients with CHB rely on direct-acting antivirals (DAAs) that suppress viral replication without eradicating HBV from the liver. Cure of CHB may well require combining these and forthcoming DAAs with immune-stimulating approaches of different nature and function. Here, we review the relative potential of these combination therapies.
乙型肝炎病毒 (HBV) 可引起急性或慢性肝脏疾病。慢性乙型肝炎 (CHB) 常进展为肝硬化和肝细胞癌。由于 HBV 极不易致细胞病变，免疫事件在感染结局中起着关键作用。事实上，适应性免疫反应在急性感染期间引发病毒清除，而病毒持续存在则反映了无法产生和维持这种反应。目前针对 CHB 患者的治疗依赖于直接作用抗病毒药物 (DAAs)，这些药物抑制病毒复制，但不能从肝脏中清除 HBV。CHB 的治愈可能需要将这些药物和即将推出的 DAA 与不同性质和功能的免疫刺激方法相结合。在这里，我们综述了这些联合疗法的相对潜力。
